Compare VRTX & FTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | FTNT |
|---|---|---|
| Founded | 1989 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Computer peripheral equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 84.6B |
| IPO Year | 2006 | 2009 |
| Metric | VRTX | FTNT |
|---|---|---|
| Price | $442.96 | $145.07 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 29 | 25 |
| Target Price | ★ $539.69 | $85.71 |
| AVG Volume (30 Days) | 1.1M | ★ 5.6M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 836.54 | 7.08 |
| EPS | ★ 4.02 | 0.72 |
| Revenue | $2,488,652,000.00 | ★ $6,799,600,000.00 |
| Revenue This Year | $10.79 | $14.02 |
| Revenue Next Year | $10.47 | $10.51 |
| P/E Ratio | ★ $108.35 | $192.74 |
| Revenue Growth | ★ 46.20 | 14.17 |
| 52 Week Low | $362.50 | $70.12 |
| 52 Week High | $509.98 | $150.07 |
| Indicator | VRTX | FTNT |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 67.31 |
| Support Level | $429.02 | $76.64 |
| Resistance Level | $461.66 | $150.07 |
| Average True Range (ATR) | 9.92 | 6.01 |
| MACD | 0.80 | -1.27 |
| Stochastic Oscillator | 77.74 | 82.95 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.